Table 5. Protective Efficacy of MAbs in Guinea Pigs Infected with GA-EBOV.
| Treatment | Treatment timea | Meantime to deathb (days) | No. of survivors/totalc | Survival (%) |
| Neutralizing MAb Combination | −1 | 11.17±3.09 (n = 3) | 3/6 | 50 |
| Neutralizing MAb Combination | +1 | 7.92±0.42 (n = 3) | 3/6 | 50 |
| Neutralizing MAb Combination | +2 | N/Ad | 6/6 | 100 |
| Neutralizing MAb Combination | +3 | 11.17±3.09 (n = 4) | 4/6 | 67 |
| PBS | +2 | 6.58±0.59 (n = 6) | 0/6 | 0 |
a
Guinea pigs were treated i.p. with a neutralizing MAb combination (2 mg 4G7+1.5 mg 1H3+1.5 mg 2G4) on the indicated days before or after challenge with 1000 LD50 GA-EBOV. The survival of the guinea pigs was followed.
b
Average time to death. (No. of animals in calculation).
c
Number of survivors at 28 dpi.
d
N/A: not applicable.